63132-39-8

Basic information

• Product Name: Olpadronate Sodium
• Synonyms: Olpadronate Sodium;Olpadronate;Olpadronic;olpadronic acid;3-(DiMethylaMino)-1-hydroxypropylidene-1,1-bisphosphonic Acid;3-DiMethylaMino-1-hydroxypropylidenebiphosphonic Acid;P,P'-[3-(DiMethylaMino)-1-hydroxypropylidene]bisphosphonic Acid
• CAS NO: 63132-39-8
• Molecular Formula: C5H15NO7P2
• Molecular Weight: 263.121
• Product Categories: Amines;Intermediates & Fine Chemicals;Pharmaceuticals;Phosphorylating and Phosphitylating Agents
• Mol File: 63132-39-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 590.1 °C at 760 mmHg
• Flash Point: 310.7 °C
• Appearance: /
• Density: 1.706 g/cm³
• Vapor Pressure: 2.21E-16mmHg at 25°C
• Refractive Index: 1.566
• PKA: 1.46±0.10(Predicted)
• CAS DataBase Reference: Olpadronate Sodium(CAS DataBase Reference)
• NIST Chemistry Reference: Olpadronate Sodium(63132-39-8)
• EPA Substance Registry System: Olpadronate Sodium(63132-39-8)

Safety Data

• Hazardous Substances Data: 63132-39-8(Hazardous Substances Data)

Usage

Uses

Olpadronic acid is used for the preparation of bisphosphonic acid derivatives as anti-osteoporosis

InChI:InChI=1/C5H15NO7P2/c1-6(2)4-3-5(7,14(8,9)10)15(11,12)13/h7H,3-4H2,1-2H3,(H2,8,9,10)(H2,11,12,13)

Upstream product

• 50-00-0 formaldehyd 
• 40391-99-9 pamidronate 
• 1738-25-6 3-dimethylaminopropiononitrile 
• 63132-38-7 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid 
• 6300-04-5 3-dimethylaminopropionic acid 

Relevant articles and documents

Preparation and application of sulfonic acid-phosphonic acid ligands

The invention relates to preparation and application of a sulfonic acid-phosphonic acid ligand. The structure of the sulfonic acid-phosphonic acid ligand comprises sulfonic acid, quaternary ammonium and phosphonic acid groups, and specifically comprises a sulfonic acid betaine-phosphonic acid ligand, a sulfonic acid-zoledronic acid ligand and a sulfonic acid-risedronic acid ligand. The molecular formula of the sulfobetaine-phosphonic acid ligand is C8H21NO10P2S, and the molecular weight of the sulfobetaine-phosphonic acid ligand is 384.2. The molecular formula of the sulfonic acid-zoledronic acid ligand is C8H16O10N2P2S, and the molecular weight of the sulfonic acid-zoledronic acid ligand is 394.23. The molecular formula of the sulfonic acid-risedronate ligand is C10H17O10NP2S, and the molecular weight of the sulfonic acid-risedronate ligand is 405.25. The sulfonic acid-phosphonic acid ligand disclosed by the invention has excellent hydrophilicity and can be coordinated with various metal elements. The molecules have important applications in the following two aspects: 1, the sulfonic acid-phosphonic acid ligand is used for modifying a hydrophobic nano material, so that the hydrophilicity of the material is remarkably improved, and the sulfonic acid-phosphonic acid ligand can be dispersed in a water phase; and 2, a certain inhibition effect is achieved on tumors.

Enteric coated formulation for bisphosphonic acids and salts thereof

Pharmaceutical compositions, processes for preparing the compositions and methods of using the composition are provided. The pharmaceutical composition comprises an inert core surrounded by an active coating containing one or more bisphosphonic acids or salts thereof, a seal coating surrounding the active coating and an enteric coating surrounding the seal coating. Alendronic acid and alendronate sodium trihydrate are the preferred active ingredients. The composition may be provided in the form of pellets in a capsule or Peltabs. The invention further provides methods for the treatment of disorders caused by the abnormal dissolution or deposition of calcium salts using the inventive compositions.

Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)

Bisphosphonates (BPs) are pyrophosphate analogues in which the oxygen in P-O-P has been replaced by a carbon, resulting in a metabolically stable P-C-P structure. Pamidronate (1b, Novartis), a second-generation BP, was the starting point for extensive SAR studies. Small changes of the structure of pamidronate lead to marked improvements of the inhibition of osteoclastic resorption potency. Alendronate (1c, MSD), with an extra methylene group in the N-alkyl chain, and olpadronate (1h, Gador), the N,N-dimethyl analogue, are about 10 times more potent than pamidronate. Extending one of the N-methyl groups of olpadronate to a pentyl substituent leads to ibandronate (1k, Roche, Boehringer-Mannheim), which is the most potent close analogue of pamidronate. Even slightly better antiresorptive potency is achieved with derivatives having a phenyl group linked via a short aliphatic tether of three to four atoms to nitrogen, the second substituent being preferentially a methyl group (e.g., 4g, 4j, 5d, or 5r). The most potent BPs are found in the series containing a heteroaromatic moiety (with at least one nitrogen atom), which is linked via a single methylene group to the geminal bisphosphonate unit. Zoledronic acid (6i), the most potent derivative, has an ED50 of 0.07 mg/kg in the TPTX in vivo assay after sc administration. It not only shows by far the highest therapeutic ratio when comparing resorption inhibition with undesired inhibition of bone mineralization but also exhibits superior renal tolerability. Zoledronic acid (6i) has thus been selected for clinical development under the registered trade name Zometa. The results of the clinical trials indicate that low doses are both efficacious and safe for the treatment of tumor-induced hypercalcemia, Paget's disease of bone, osteolytic metastases, and postmenopausal osteoporosis.